Your session is about to expire
← Back to Search
Proton Beam Radiation for Wilms Tumor
Study Summary
This trial is for patients with Wilms Tumor cancer who will have proton beam radiation to a conformal reduced target volume in the flank. The objective is to allow normal flank growth compared to the contralateral untreated side and non-irradiated patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had radiation therapy targeted at my abdomen.I have had radiation therapy before but may need it again for this trial.I have followed the specific chemotherapy plan outlined for my condition and may switch based on my response.I am a woman who can have children and have a negative pregnancy test.My cancer is at stage I or II, and I am eligible for surgery and biological treatment.I am diagnosed with Wilms tumor.I will start radiation therapy within 28 days after my surgery, aiming for day 21.My Wilms tumor was surgically removed and had a favorable type.My tumor has a type of cell that disqualifies me from the treatment part of the study.I am at the initial stages of being diagnosed with Wilms tumor.I am mostly able to care for myself and carry out daily activities.
- Group 1: Stage V Adjuvant RT:
- Group 2: Favorable Histology Stage I & II and FH Stage III/IV
- Group 3: Stage III & IV Adjuvant RT and Stage V
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment open for this research program?
"According to the data on clinicaltrials.gov, this trial is currently open for recruitment and has been since its initial post date of August 19th 2021. The information was last updated on September 1st 2022."
What is the aggregate figure of participants for this research?
"Verified. The clinicaltrials.gov website confirms that this trial, which was first posted on August 19th 2021, is actively recruiting participants. 95 individuals are required to be recruited from a single medical site."
What potential repercussions could patients encounter when undergoing Favorable Histology Stages I & II and FH Stage III/IV?
"Due to its Phase 2 status, our team at Power has assigned Favorable Histology Stage I & II and FH Stage III/IV a safety rating of 2 on the scale from 1 – 3. This is based off existing evidence that suggests their level of security but lack of data verifying efficacy."
Share this study with friends
Copy Link
Messenger